Pharma Market Intelligence: What Most Teams Get Wrong

Pharma market intelligence is the structured process of gathering, analysing, and acting on competitive, clinical, and commercial data to inform drug development, launch strategy, and brand positioning. Done well, it tells you not just what competitors are doing, but why the market is moving the way it is, and where the gaps are before your rivals see them.

The problem is that most pharma teams confuse data collection with intelligence. They have dashboards, syndicated reports, and analyst subscriptions. What they often lack is a clear commercial question that all of that data is supposed to answer.

I spent a period early in my career working on campaigns where the brief was built almost entirely on syndicated market data. The data was expensive, the reports were thorough, and the strategy was almost completely wrong. Not because the data was inaccurate, but because nobody had asked whether it was measuring the right thing. That experience shaped how I think about market research at every level. If you want the broader framework behind that thinking, the Market Research and Competitive Intel hub covers the principles that apply across industries, not just pharma.

Why Pharma Intelligence Programmes Produce Reports Nobody Acts On

The structural problem in most pharma intelligence functions is that they were built to satisfy a compliance or governance need, not a commercial one. Someone decided the organisation needed a competitive intelligence programme, a team was hired or a vendor was contracted, and a cadence of reports was established. The reports land in inboxes. People skim them. Decisions get made without them.

This is not a pharma-specific failure. I have seen it in technology, financial services, and retail. But pharma is where it is most expensive, because the commercial stakes are higher and the lead times are longer. A missed signal about a competitor’s Phase III trial can have consequences that play out over five years, not five months.

The fix is not a better dashboard. It is a clearer definition of the decisions the intelligence programme is supposed to support. What are the three or four commercial questions that, if answered well, would change how this brand or pipeline asset is positioned? Everything else is background noise.

This connects directly to how you define your audience for intelligence purposes. The discipline of ICP scoring and customer definition, while typically applied in B2B SaaS contexts, contains a rigour that pharma intelligence teams would benefit from borrowing. Who is the internal customer for this intelligence? What decision are they making? What would change their position? Those questions sharpen a programme faster than any new data source.

Where the Most Useful Pharma Intelligence Actually Lives

The instinct in regulated industries is to rely on official, sanctioned sources: FDA filings, published clinical trial results, earnings calls, and analyst reports. These are legitimate inputs. They are also the same inputs every competitor is reading.

The intelligence that creates genuine competitive advantage tends to come from less obvious places. Conference abstracts published six months before the full paper. Patent filings that signal a formulation change before any press release. HCP discussion forums where prescribing behaviour shifts before it shows up in prescription data. Procurement signals from hospital formulary committees. Regulatory agency meeting minutes. These sources require more effort to process, but they carry signal that syndicated data does not.

There is a category of research that sits between official sources and primary intelligence gathering that is worth understanding properly. Grey market research covers this territory: the informal, semi-public, and non-syndicated data that falls between what vendors sell and what regulators publish. In pharma, this includes everything from conference poster sessions to KOL social media activity. Treating it systematically, rather than opportunistically, changes what your intelligence programme can see.

When I was at iProspect, growing the agency from around 20 people to over 100, one of the things I noticed consistently was that the clients who were most commercially effective were not the ones with the biggest research budgets. They were the ones who had figured out where the unconventional signal was in their market and built a process around capturing it. In pharma, that means having someone whose job is to monitor the grey zone, not just the official record.

The Role of Digital Signals in a Pharma Intelligence Stack

Pharma has been slower than most industries to integrate digital signals into its intelligence programmes, and the reasons are understandable. Regulatory constraints around promotional activity, concerns about patient data, and a traditional reliance on sales force feedback have all created inertia. But digital signals are now too significant to treat as supplementary.

Search behaviour, in particular, has become one of the more reliable leading indicators of market movement. When HCPs or patients start searching for a condition or treatment in new ways, it often precedes a shift in prescribing patterns or patient expectations. Search engine marketing intelligence is not just a performance marketing tool. Used analytically, it reveals demand signals that traditional market research misses entirely.

Early in my career, around 2000, I was running a paid search campaign for a music festival at lastminute.com. The campaign was relatively straightforward, but what struck me was how immediately the search data told you whether the market was interested. Six figures of revenue in roughly a day, not because the campaign was sophisticated, but because we were reading demand signals in real time and responding to them. Pharma intelligence teams have access to the same kind of signal. Most are not using it with anything like that responsiveness.

The BCG analysis on how organisations get digital transformation right makes a point that applies directly here: digital tools do not create intelligence capability. Organisational readiness to act on digital signals does. A pharma team that has search data but no process for routing it to the brand team is no better off than one that does not have it at all.

Qualitative Research in a Quantitative Industry

Pharma is a numbers industry. Clinical endpoints, prescription volumes, market share percentages, payer coverage rates. The quantitative infrastructure is extensive. What often gets underweighted is the qualitative layer that explains why the numbers are moving the way they are.

HCP attitudes toward a new mechanism of action, patient experience of a dosing regimen, payer committee sentiment toward a therapeutic class, the informal networks through which prescribing habits spread among specialists. These are not things a database tells you. They require structured qualitative research, conducted properly, with the right participants.

The methodology matters more than most teams acknowledge. Focus group methodology in regulated industries is not the same as consumer research. The participant selection, the moderation approach, the analysis framework, all of these need to be calibrated for an audience that has professional constraints on what they can say and how they say it. Getting this wrong produces data that feels rich but misleads.

I have judged the Effie Awards, which means I have seen behind the curtain on a significant number of marketing effectiveness cases. The campaigns that consistently underperformed were not the ones with weak creative or poor media planning. They were the ones where the qualitative understanding of the audience was thin. The team knew the demographics. They did not know the mindset. In pharma, that gap between demographic knowledge and psychological understanding of HCP or patient behaviour is where a lot of launch strategies quietly fail.

Aligning Intelligence to Commercial Strategy, Not Just Research Calendars

One of the more persistent structural problems in pharma intelligence is the disconnect between when research is conducted and when decisions are actually made. Research calendars are often set annually. Commercial decisions happen continuously. The result is that the intelligence programme is always slightly out of phase with the questions the business is actually asking.

Fixing this requires treating intelligence as a strategic function rather than a research function. The distinction matters. A research function produces outputs on a schedule. A strategic intelligence function is organised around decision points: launch readiness reviews, lifecycle management decisions, pricing negotiations, pipeline prioritisation. The intelligence is timed to inform those moments, not to fulfil a reporting obligation.

This is essentially the same challenge that technology consultancies face when trying to align their analytical capabilities with business strategy. The framework for aligning technology consulting with business strategy, including SWOT analysis and ROI mapping, translates directly to how a pharma intelligence programme should be structured. The question is always: what decision does this serve, and what is the cost of getting it wrong?

When I was turning around a loss-making agency business, one of the first things I did was map every piece of analysis we were producing to a specific commercial decision. Anything that could not be connected to a decision got cut. The team initially pushed back. Within a quarter, the quality of the work that remained had improved significantly, because everyone understood what it was for. The same logic applies to a pharma intelligence function with too many workstreams and not enough clarity on what they are meant to change.

Understanding the Pain Points That Competitors Are Not Addressing

Competitive intelligence in pharma tends to focus on what competitors are doing: their pipeline, their clinical data, their promotional spend, their market share. What it often misses is what competitors are failing to do, specifically, the unmet needs they are not addressing and the friction points in their customer experience that create an opening.

This is where pain point research becomes a genuine competitive tool rather than a customer service exercise. In pharma, the pain points are layered: HCP pain points around prescribing complexity, patient pain points around adherence and side effect management, payer pain points around formulary justification, and system pain points around access and administration. Each layer represents a potential differentiation point if your brand can address it credibly.

The brands that have created durable market positions in competitive therapeutic areas have almost always done so by identifying a pain point that the market leader was structurally unable to address, usually because addressing it would require the leader to change something fundamental about their product or their commercial model. Finding that opening requires intelligence that goes beyond clinical differentiation into the operational and experiential realities of prescribing and patient management.

Back when I first moved into marketing, I asked the managing director for budget to build a new website. The answer was no. So I taught myself to code and built it myself. The lesson was not about resourcefulness for its own sake. It was that when you cannot get what you need through conventional channels, you find an unconventional route. The same instinct applies to pharma intelligence. If the syndicated data does not answer your commercial question, you do not wait for a better report. You design a research approach that gets at the answer directly.

Building an Intelligence Programme That Actually Changes Decisions

The measure of a pharma intelligence programme is not the quality of its outputs. It is the quality of the decisions it influences. That sounds obvious, but most programmes are evaluated on the former, not the latter.

Building a programme that changes decisions requires three things that most organisations underinvest in. First, a clear taxonomy of the decisions the programme is meant to support, mapped to the commercial calendar. Second, a feedback mechanism that routes intelligence to the right people at the right time, not into a shared drive that nobody opens. Third, a review process that asks, after each major decision, whether the intelligence was used, whether it was useful, and what was missing.

The third element is the one that almost never happens. Post-decision reviews of intelligence quality are rare, which means programmes never improve their targeting. They produce more of what they have always produced, regardless of whether it is what the business actually needs.

Across the 30-plus industries I have worked in over two decades, the organisations with the strongest market intelligence capability share one characteristic: they treat intelligence as a conversation between the research function and the commercial function, not a one-way broadcast. The commercial team defines the questions. The intelligence team answers them. The commercial team responds with what changed as a result. That loop, sustained over time, is what separates a programme that matters from one that fills a folder.

If you are building or rebuilding a pharma intelligence capability, the principles covered across the Market Research and Competitive Intel hub provide a grounding in the methodological and strategic foundations that apply regardless of sector. Pharma has its regulatory and structural peculiarities, but the core discipline of asking the right question before you design the research is universal.

About the Author

Keith Lacy is a marketing strategist and former agency CEO with 20+ years of experience across agency leadership, performance marketing, and commercial strategy. He writes The Marketing Juice to cut through the noise and share what works.

Frequently Asked Questions